RU2017115193A - Производные бороновой кислоты - Google Patents
Производные бороновой кислоты Download PDFInfo
- Publication number
- RU2017115193A RU2017115193A RU2017115193A RU2017115193A RU2017115193A RU 2017115193 A RU2017115193 A RU 2017115193A RU 2017115193 A RU2017115193 A RU 2017115193A RU 2017115193 A RU2017115193 A RU 2017115193A RU 2017115193 A RU2017115193 A RU 2017115193A
- Authority
- RU
- Russia
- Prior art keywords
- ethyl
- boronic acid
- propanoylamino
- och
- independently
- Prior art date
Links
- 150000001642 boronic acid derivatives Chemical class 0.000 title 1
- -1 monocyclic hydrocarbon Chemical class 0.000 claims 95
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 15
- 229940002612 prodrug Drugs 0.000 claims 14
- 239000000651 prodrug Substances 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 10
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 6
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 102100030978 Cytochrome c oxidase assembly factor 1 homolog Human genes 0.000 claims 4
- 101000919635 Homo sapiens Cytochrome c oxidase assembly factor 1 homolog Proteins 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 3
- 239000004215 Carbon black (E152) Substances 0.000 claims 3
- 229930195733 hydrocarbon Natural products 0.000 claims 3
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004799 bromophenyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001207 fluorophenyl group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000007365 immunoregulation Effects 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000003944 tolyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 claims 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 claims 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims 1
- 125000005916 2-methylpentyl group Chemical group 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000005917 3-methylpentyl group Chemical group 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- JBBZHDUAZGQYDB-HNNXBMFYSA-N C(C)C=1C=C(C=CC=1)C[C@H](NC(CCCN1C(OCC1)=O)=O)B(O)O Chemical compound C(C)C=1C=C(C=CC=1)C[C@H](NC(CCCN1C(OCC1)=O)=O)B(O)O JBBZHDUAZGQYDB-HNNXBMFYSA-N 0.000 claims 1
- MAOAWTHWFXKENT-KRWDZBQOSA-N C1(=CC=CC2=CC=CC=C12)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O Chemical compound C1(=CC=CC2=CC=CC=C12)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O MAOAWTHWFXKENT-KRWDZBQOSA-N 0.000 claims 1
- BHAGHLXSAMHHFC-SFHVURJKSA-N C1(=CC=CC2=CC=CC=C12)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O Chemical compound C1(=CC=CC2=CC=CC=C12)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O BHAGHLXSAMHHFC-SFHVURJKSA-N 0.000 claims 1
- FJZCGDMFIUBZMZ-KRWDZBQOSA-N C1=C(C=CC2=CC=CC=C12)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O Chemical compound C1=C(C=CC2=CC=CC=C12)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O FJZCGDMFIUBZMZ-KRWDZBQOSA-N 0.000 claims 1
- JICJBTVXQHUWSP-SFHVURJKSA-N C1=C(C=CC2=CC=CC=C12)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O Chemical compound C1=C(C=CC2=CC=CC=C12)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O JICJBTVXQHUWSP-SFHVURJKSA-N 0.000 claims 1
- LCRPEFPIXJFHFF-INIZCTEOSA-N CC1(N(C(CC1)=O)CCC(=O)N[C@@H](CC1=COC2=C1C=CC=C2C)B(O)O)C Chemical compound CC1(N(C(CC1)=O)CCC(=O)N[C@@H](CC1=COC2=C1C=CC=C2C)B(O)O)C LCRPEFPIXJFHFF-INIZCTEOSA-N 0.000 claims 1
- VPSSAUKXMUYTIZ-GGYWPGCISA-N CC1=C(C=CC(=C1)C)C[C@H](NC(=O)C1N(C(CC1)=O)C1=CC=CC=C1)B(O)O Chemical compound CC1=C(C=CC(=C1)C)C[C@H](NC(=O)C1N(C(CC1)=O)C1=CC=CC=C1)B(O)O VPSSAUKXMUYTIZ-GGYWPGCISA-N 0.000 claims 1
- WBXXDPGDRXIQDC-INIZCTEOSA-N CC1=C(C=CC(=C1)C)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O Chemical compound CC1=C(C=CC(=C1)C)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O WBXXDPGDRXIQDC-INIZCTEOSA-N 0.000 claims 1
- LRUFFNYOIKWFAE-ZBFHGGJFSA-N CC1=CC=CC=2[C@@H](COC=21)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O Chemical compound CC1=CC=CC=2[C@@H](COC=21)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O LRUFFNYOIKWFAE-ZBFHGGJFSA-N 0.000 claims 1
- JFRNNMQWKOWFGC-HNNXBMFYSA-N CC=1C=C(C=CC=1C)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O Chemical compound CC=1C=C(C=CC=1C)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O JFRNNMQWKOWFGC-HNNXBMFYSA-N 0.000 claims 1
- CUYSWUJVSGYBDG-INIZCTEOSA-N CC=1C=C(C=CC=1C)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O Chemical compound CC=1C=C(C=CC=1C)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O CUYSWUJVSGYBDG-INIZCTEOSA-N 0.000 claims 1
- XLQOLSITCRGFQL-INIZCTEOSA-N CCN1CCN(CCC(=O)N[C@@H](CC2=COC3=CC=CC=C23)B(O)O)C(=O)C1=O Chemical compound CCN1CCN(CCC(=O)N[C@@H](CC2=COC3=CC=CC=C23)B(O)O)C(=O)C1=O XLQOLSITCRGFQL-INIZCTEOSA-N 0.000 claims 1
- PDWIBYAJMPZXMB-HNNXBMFYSA-N COCC1=CC=C(C=C1)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O Chemical compound COCC1=CC=C(C=C1)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O PDWIBYAJMPZXMB-HNNXBMFYSA-N 0.000 claims 1
- CRMLLLSNOPJFLC-SFHVURJKSA-N FC1=CC=C(C=C1)C[C@H](NC(CCN1C(N(CC1)C1=CC=CC=C1)=O)=O)B(O)O Chemical compound FC1=CC=C(C=C1)C[C@H](NC(CCN1C(N(CC1)C1=CC=CC=C1)=O)=O)B(O)O CRMLLLSNOPJFLC-SFHVURJKSA-N 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- ZIKLJXNVZXIUHJ-IJHRGXPZSA-N O1C=C(C2=C1C=CC=C2)C[C@H](NC(=O)C1N(CCC1)C1=CC=CC=C1)B(O)O Chemical compound O1C=C(C2=C1C=CC=C2)C[C@H](NC(=O)C1N(CCC1)C1=CC=CC=C1)B(O)O ZIKLJXNVZXIUHJ-IJHRGXPZSA-N 0.000 claims 1
- KLEUVJSQTIKBHS-HNNXBMFYSA-N O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O Chemical compound O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O KLEUVJSQTIKBHS-HNNXBMFYSA-N 0.000 claims 1
- DZDFAOCRAKFTFD-INIZCTEOSA-N O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(CCC1=O)(C)C)=O)B(O)O Chemical compound O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(CCC1=O)(C)C)=O)B(O)O DZDFAOCRAKFTFD-INIZCTEOSA-N 0.000 claims 1
- JPDTXCPUVRRXHE-INIZCTEOSA-N O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O Chemical compound O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(CCCC1)=O)=O)B(O)O JPDTXCPUVRRXHE-INIZCTEOSA-N 0.000 claims 1
- ZDZJKLCPDMMXAK-INIZCTEOSA-N O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(CN(CC1)C)=O)=O)B(O)O Chemical compound O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(CN(CC1)C)=O)=O)B(O)O ZDZJKLCPDMMXAK-INIZCTEOSA-N 0.000 claims 1
- XBRMXJNNIVEVET-HNNXBMFYSA-N O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(COCC1)=O)=O)B(O)O Chemical compound O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(COCC1)=O)=O)B(O)O XBRMXJNNIVEVET-HNNXBMFYSA-N 0.000 claims 1
- QBILDWJRAGKJKQ-ANYOKISRSA-N O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(OC(C1)C1=CC=CC=C1)=O)=O)B(O)O Chemical compound O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCN1C(OC(C1)C1=CC=CC=C1)=O)=O)B(O)O QBILDWJRAGKJKQ-ANYOKISRSA-N 0.000 claims 1
- XQSAXTVLXDNRHV-LBPRGKRZSA-N O1C=C(C2=C1C=CC=C2)C[C@H](NC(CN1C(SCC1=O)=O)=O)B(O)O Chemical compound O1C=C(C2=C1C=CC=C2)C[C@H](NC(CN1C(SCC1=O)=O)=O)B(O)O XQSAXTVLXDNRHV-LBPRGKRZSA-N 0.000 claims 1
- MVXSDNYSLPRPRW-HNNXBMFYSA-N O1CCOC2=C1C=CC(=C2)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O Chemical compound O1CCOC2=C1C=CC(=C2)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O MVXSDNYSLPRPRW-HNNXBMFYSA-N 0.000 claims 1
- ZUPCERTWSGUXQH-DOMZBBRYSA-N O1C[C@H](C2=C1C=CC=C2)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O Chemical compound O1C[C@H](C2=C1C=CC=C2)C[C@H](NC(CCN1C(CCC1)=O)=O)B(O)O ZUPCERTWSGUXQH-DOMZBBRYSA-N 0.000 claims 1
- JZDKWBYDTKBMQY-ZDUSSCGKSA-N O=C1N(C(CCC1)=O)CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O Chemical compound O=C1N(C(CCC1)=O)CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O JZDKWBYDTKBMQY-ZDUSSCGKSA-N 0.000 claims 1
- JGYYJKNWDIBPOX-GGYWPGCISA-N O=C1N(CC(C1)C1=CC=CC=C1)CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O Chemical compound O=C1N(CC(C1)C1=CC=CC=C1)CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O JGYYJKNWDIBPOX-GGYWPGCISA-N 0.000 claims 1
- NLFBGBHCMKFZGL-CYBMUJFWSA-N O=C1N(CCC1)CCC(=O)N[C@H](CC1=CC=CC=C1)B(O)O Chemical compound O=C1N(CCC1)CCC(=O)N[C@H](CC1=CC=CC=C1)B(O)O NLFBGBHCMKFZGL-CYBMUJFWSA-N 0.000 claims 1
- HKEJQSDOJCWYPZ-CQSZACIVSA-N O=C1N(CCCC1)CCC(=O)N[C@H](CC1=CC=CC=C1)B(O)O Chemical compound O=C1N(CCCC1)CCC(=O)N[C@H](CC1=CC=CC=C1)B(O)O HKEJQSDOJCWYPZ-CQSZACIVSA-N 0.000 claims 1
- SBOZBULALIMTBG-HNNXBMFYSA-N O=C1N(CCCCC1)CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O Chemical compound O=C1N(CCCCC1)CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O SBOZBULALIMTBG-HNNXBMFYSA-N 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14003390.3 | 2014-10-01 | ||
| EP14003390 | 2014-10-01 | ||
| PCT/EP2015/001930 WO2016050355A1 (en) | 2014-10-01 | 2015-10-01 | Boronic acid derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017115193A true RU2017115193A (ru) | 2018-11-06 |
| RU2017115193A3 RU2017115193A3 (enExample) | 2019-02-08 |
Family
ID=51690787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017115193A RU2017115193A (ru) | 2014-10-01 | 2015-10-01 | Производные бороновой кислоты |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10640520B2 (enExample) |
| EP (1) | EP3201205B1 (enExample) |
| JP (1) | JP6835710B2 (enExample) |
| KR (1) | KR20170066506A (enExample) |
| CN (1) | CN107108660B (enExample) |
| AU (1) | AU2015327411B2 (enExample) |
| BR (1) | BR112017006368A2 (enExample) |
| CA (1) | CA2963186A1 (enExample) |
| ES (1) | ES2811273T3 (enExample) |
| IL (1) | IL251300A0 (enExample) |
| MX (1) | MX2017004037A (enExample) |
| RU (1) | RU2017115193A (enExample) |
| SG (1) | SG11201702625PA (enExample) |
| WO (1) | WO2016050355A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3201207B1 (en) | 2014-10-01 | 2021-02-24 | Merck Patent GmbH | Boronic acid derivatives |
| CA2963198A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| KR102457840B1 (ko) | 2014-10-01 | 2022-10-21 | 메르크 파텐트 게엠베하 | 보론산 유도체 |
| JP7289828B2 (ja) * | 2017-08-23 | 2023-06-12 | ケザール ライフ サイエンシズ | 自己免疫疾患の治療における免疫プロテアソーム阻害剤および免疫抑制剤 |
| KR20200040295A (ko) | 2017-08-24 | 2020-04-17 | 메르크 파텐트 게엠베하 | 보론산 유도체 |
| CA3107377A1 (en) * | 2018-07-26 | 2020-01-30 | Merck Patent Gmbh | Boronic acid derivatives |
| EP3860574A1 (en) | 2018-10-04 | 2021-08-11 | Kezar Life Sciences | Immunoproteasome inhibitor formulation |
| CN113135943A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| CN113135944A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| JP7568432B2 (ja) * | 2020-07-01 | 2024-10-16 | リファインホールディングス株式会社 | モルホリン誘導体およびその製造方法 |
| CN114075227B (zh) | 2020-08-19 | 2023-07-04 | 北京嵩润医药科技有限责任公司 | 吡唑硼酸类化合物、包含其的药物组合物及它们的用途 |
| EP4301466A4 (en) * | 2021-03-02 | 2025-08-20 | Univ Case Western Reserve | BETA-LACTAMASE INHIBITORS AND THEIR USES |
| JP7758028B2 (ja) * | 2021-03-05 | 2025-10-22 | Ａｇｃ株式会社 | 化合物、化合物の製造方法及び表面処理剤の製造方法 |
| EP4377324A1 (en) | 2021-07-29 | 2024-06-05 | Merck Patent GmbH | Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain |
| WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
| CN120736500A (zh) * | 2025-08-25 | 2025-10-03 | 安徽得壹能源科技有限公司 | 一种磷酸铁锂正极材料、其制备方法及电池 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563127A (en) * | 1993-03-24 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
| IL111175A0 (en) * | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| US6060462A (en) * | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
| FR2758329B1 (fr) * | 1997-01-16 | 1999-02-12 | Synthelabo | Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique |
| AR069463A1 (es) * | 2007-11-13 | 2010-01-27 | Protez Pharmaceuticals Inc | Inhibidores de beta-lactamasa |
| US20100120715A1 (en) * | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| AR075090A1 (es) * | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| KR20140114391A (ko) * | 2011-12-22 | 2014-09-26 | 아레스 트레이딩 에스.에이. | 알파-아미노 보론산 유도체, 선택적 면역프로테아좀 저해인자 |
| WO2014151958A1 (en) * | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP3201207B1 (en) | 2014-10-01 | 2021-02-24 | Merck Patent GmbH | Boronic acid derivatives |
| KR102457840B1 (ko) | 2014-10-01 | 2022-10-21 | 메르크 파텐트 게엠베하 | 보론산 유도체 |
| CA2963198A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
-
2015
- 2015-10-01 CA CA2963186A patent/CA2963186A1/en active Pending
- 2015-10-01 US US15/516,420 patent/US10640520B2/en active Active
- 2015-10-01 SG SG11201702625PA patent/SG11201702625PA/en unknown
- 2015-10-01 AU AU2015327411A patent/AU2015327411B2/en not_active Ceased
- 2015-10-01 JP JP2017518069A patent/JP6835710B2/ja not_active Expired - Fee Related
- 2015-10-01 WO PCT/EP2015/001930 patent/WO2016050355A1/en not_active Ceased
- 2015-10-01 CN CN201580053424.7A patent/CN107108660B/zh not_active Expired - Fee Related
- 2015-10-01 MX MX2017004037A patent/MX2017004037A/es unknown
- 2015-10-01 RU RU2017115193A patent/RU2017115193A/ru not_active Application Discontinuation
- 2015-10-01 ES ES15775380T patent/ES2811273T3/es active Active
- 2015-10-01 BR BR112017006368A patent/BR112017006368A2/pt not_active IP Right Cessation
- 2015-10-01 EP EP15775380.7A patent/EP3201205B1/en active Active
- 2015-10-01 KR KR1020177011627A patent/KR20170066506A/ko not_active Withdrawn
-
2017
- 2017-03-21 IL IL251300A patent/IL251300A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016050355A1 (en) | 2016-04-07 |
| CN107108660B (zh) | 2020-09-15 |
| AU2015327411B2 (en) | 2020-01-02 |
| AU2015327411A1 (en) | 2017-05-18 |
| CN107108660A (zh) | 2017-08-29 |
| ES2811273T3 (es) | 2021-03-11 |
| RU2017115193A3 (enExample) | 2019-02-08 |
| JP6835710B2 (ja) | 2021-02-24 |
| EP3201205B1 (en) | 2020-05-13 |
| MX2017004037A (es) | 2017-07-04 |
| BR112017006368A2 (pt) | 2017-12-19 |
| KR20170066506A (ko) | 2017-06-14 |
| CA2963186A1 (en) | 2016-04-07 |
| JP2018502049A (ja) | 2018-01-25 |
| US10640520B2 (en) | 2020-05-05 |
| US20180179231A1 (en) | 2018-06-28 |
| SG11201702625PA (en) | 2017-04-27 |
| IL251300A0 (en) | 2017-05-29 |
| EP3201205A1 (en) | 2017-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017115193A (ru) | Производные бороновой кислоты | |
| RU2017115191A (ru) | Производные бороновой кислоты | |
| RU2017115188A (ru) | Производные бороновой кислоты | |
| RU2017115192A (ru) | Производные бороновой кислоты | |
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| EP3419974B1 (en) | Process for the separation of enantiomers of piperazine derivatives | |
| RU2442779C2 (ru) | Производные 2,4,5-трифенилимидазолина как ингибиторы взаимодействия между белками p53 и mdm2, предназначенные для применения в качестве противораковых средств | |
| RU2013158996A (ru) | Замещенные пиридопиразины как новые ингибиторы syk | |
| JP2015512939A5 (enExample) | ||
| RU2342383C2 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5 | |
| RU2006107785A (ru) | 2, 4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| EP3154957A1 (en) | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases | |
| RU2004122414A (ru) | Цис-2,4,5-трифенилимидазолины и их применение для лечения опухолевых заболеваний | |
| BG65207B1 (bg) | Производни на хетероциклен карбамид и използването им за инхибиране на raf киназа | |
| RU2010154172A (ru) | Соединения для лечения рака | |
| JP2020186251A (ja) | Ｂｅｔ蛋白質分解誘導作用を有するアミド化合物及びその医薬としての用途 | |
| WO2014003424A1 (ko) | 신규 레바미피드 전구체 및 그 제조방법과 용도 | |
| CZ20032645A3 (cs) | Nové kyanosubstituované dihydropyrimidinové sloučeniny a jejich použití pro léčení nemocí | |
| RU2008119994A (ru) | Ингибиторы калиевых каналов | |
| KR102729308B1 (ko) | 티오펜 유도체 및 그의 용도 | |
| WO2021101854A1 (en) | Compounds and methods of preparing compounds s1p1 modulators | |
| NO20005200L (no) | Nye polycykliske azaindolforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem | |
| RU2015117578A (ru) | Кетоамидные ингибиторы иммунопротеасом | |
| RU2007140578A (ru) | Ацилгидразиды в качестве ингибиторов киназ, в особенности для sgk | |
| RU2482117C2 (ru) | Производное 3, 8-диаминотетрагидрохинолина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190930 |